Article Text

Download PDFPDF
CASE REPORT
Mycobacterium ChelonaeDeveloping Multidrug Resistance
  1. Vinod Kumar Mannelli1,
  2. Manoj P Rai1,
  3. Divyesh Reddy Nemakayala2,
  4. Naga Preethi Kadiri1
  1. 1Department of Internal Medicine, Michigan State University, Lansing, Michigan, USA
  2. 2Internal Medicine, Sparrow Health System, Lansing, Michigan, USA
  1. Correspondence to Dr Manoj P Rai, manoj.rai{at}hc.msu.edu

Summary

Mycobacterium chelonae is a rapidly growing mycobacterium which is known to respond well to standard antibiotic treatment regimen. There are no specific guidelines for treatment. Antibiotics are chosen based on the bacterial sensitivity. Here we present a 47-year-old man with hip replacement who developed bright red papular generalised skin lesions and bilateral hip abscess. On workup, it was confirmed that M. chelonae was the causative organism. He was given 8 weeks of antibiotics; however, there was worsening of the hip abscess on interval imaging. The progression was most likely due to M. chelonae developing antibiotic resistance. Physicians should be aware of the rising resistance of this organism, and guide antibiotic therapy based on bacterial sensitivity to yield better outcomes.

  • infections
  • drugs: infectious diseases

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors VKM wrote the case; NPK assisted him with it. Both VKM and NPK assisted with literature search. The rest of the draft such as introduction, discussion and learning points were written and edited by MPR and DRN. The patient consent was obtained by MPR. VKM helped to obtain the pictures from the abdomen and forearm after getting consent from the patient.

  • Funding This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.